Agensys and Genentech entered into exclusive license agreement to discover, develop and commercialize therapeutic and diagnostic products of two Agensys cancer targets. Genentech also receives rights to certain monoclonal antibodies and to develop and commercialize all the products except vaccines and certain diagnostic applications, to which Agensys retains the rights.